{
    "clinical_study": {
        "@rank": "104220", 
        "arm_group": {
            "arm_group_label": "[C14] selumetinib 75mg single dose", 
            "arm_group_type": "Experimental", 
            "description": "[C14] selumetinib 75mg single dose"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose\n      [14C] selumetinib in volunteers"
        }, 
        "brief_title": "Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Solid Tumours", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures.\n\n          -  Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50\n             kg and no more than 100 kg, inclusive.\n\n          -  Regular bowel movements (ie, on average production of at least 1 stool per day).\n\n        Exclusion Criteria:\n\n          -  Current or past history of central serous retinopathy or retinal vein thrombosis,\n             intraocular pressure greater than 21 mmHg or uncontrolled glaucoma.\n\n          -  Exposure to radiation levels above background  exceeding 5 mSv in the last 12 months\n             or 10 mSv in the last 5 years.\n\n          -  History or presence of any clinically significant disease or disorder in the opinion\n             of the investigator\n\n          -  Any clinically important abnormalities in clinical chemistry, haematology, or\n             urinalysis results, vital signs or ECG at baseline in the opinion of the\n             Investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931761", 
            "org_study_id": "D1532C00077"
        }, 
        "intervention": {
            "arm_group_label": "[C14] selumetinib 75mg single dose", 
            "description": "Single oral administration [C14] 75mg", 
            "intervention_name": "[C14] selumetinib (oral)", 
            "intervention_type": "Drug", 
            "other_name": "Selumetinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics, mass balance, AZD6244", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ruddington", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "University of Aberdeen", 
            "last_name": "Stuart Mair, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Concentration of total radioactivity in blood and plasma and percentage of radioactive dose in urine and faeces and total balance", 
            "safety_issue": "No", 
            "time_frame": "Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Metabolite profiling and identification in plasma and excreta", 
                "safety_issue": "No", 
                "time_frame": "Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days."
            }, 
            {
                "description": "Cmax, tmax, t\u00bd, AUC, CL/F, Vz/F, MRT, fe, Ae, CLR", 
                "measure": "Pharmacokinetic parameters of selumetinib", 
                "safety_issue": "No", 
                "time_frame": "Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days."
            }, 
            {
                "measure": "Plasma concentrations of selumetinib", 
                "safety_issue": "No", 
                "time_frame": "Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days"
            }, 
            {
                "description": "Adverse events, vital signs, electrocardiogram, haematology, clinical chemistry, urinalysis, physical examination, left ventricular ejection fraction, and opthalmology assessments.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Assessments prior to treatment and after treatment including follow up."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}